Roy Golan is a registered CPA with a broad experience in Nasdaq, IPOs and M&As. Prior to the merger with Ayala Pharmaceuticals, Roy served as Executive Vice President & CFO of Biosight, a biotech company developing innovative therapeutics for hematological malignancies and disorders. He has held several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two follow-on offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of $1.1 billion. Roy started his career at PriceWaterhouseCoopers (PwC), is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LLM in Law from Bar Ilan University.